Results 41 to 50 of about 22,482 (226)

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom

Life
(1) Aim: To evaluate early real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom. (2) Methods: This retrospective, observational study included 59 eyes from 50 patients
M. Musadiq, M. Musadiq, Fozia Latif, Benjamin Ng, Matthew Azzopardi, N. Gilead, A. Needham, Yu Jeat Chong   +7 more
semanticscholar   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

Ziv-aflibercept in macular disease [PDF]

, 2015
Background/aims Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved ...
Mansour, Ahmad Mohammed Farid Mahmoud, I Al-Ghadban, Sara, Younis, Muhammad H., El-Sabban, Marwan E.   +3 more
core   +1 more source

El efecto del agente antiangiogénico aflibercept sobre la endometriosis inducida quirúrgicamente en un modelo de rata

Cirugía y Cirujanos
Objetivo: Mostrar por primera vez cómo afecta aflibercept a las lesiones de endometriosis. Material y métodos: Endometriosis inducida quirúrgicamente en ratas hembras albinas Wistar. Las ratas con endometriosis se dividieron aleatoriamente en tres grupos:
Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay   +3 more
doaj   +1 more source

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial.

Ophthalmology (Rochester, Minn.)
PURPOSE To follow up the previously published comparison of aflibercept 8 mg at extended dosing intervals versus aflibercept 2 mg every 8 weeks (2q8) in patients with diabetic macular edema (DME) through 48 weeks, we now report efficacy, durability, and ...
Diana V. Do, C. Wykoff, S. Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, A. Seres, Alyson J. Berliner, Sergio Leal, R. Vitti, Karen W. Chu, Kim Reed, Yenchieh Cheng, R. Bhore, Zhanying Bai, U. Schmidt-Ott, T. Schmelter, Andrea Schulze, Z. Hasanbasic, Peter Morgan-Warren, Xin Zhang, Boaz Hirshberg, G. Yancopoulos   +25 more
semanticscholar   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source

Aflibercept in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2012
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment.
Wang, Tzu-Fei, Tzu-Fei Wang, Albert Craig Lockhart, Lockhart, Albert Craig   +3 more
core   +1 more source

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema

Ophthalmology Retina
Purpose: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME).
Jennifer I. Lim, Manuel Amador, D. Dhoot, Avni P. Finn, S. Fraser-bell, Kara Gibson, Oluwatobi O. Idowu, Rahul N. Khurana, P. Lanzetta, Tai-Chi Lin, Florie Mar, A. Pollreisz, Aleksandra V. Rachitskaya, P. Schlottmann, Yannan Tang, T. Lai   +15 more
semanticscholar   +1 more source

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review

International Journal of Molecular Sciences, 2022
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries.
Sławomir Liberski, M. Wichrowska, J. Kocięcki   +2 more
semanticscholar   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source